🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mainpal Rana

University of Pittsburgh

ORCID: 0000-0003-2458-7259

Also affiliated with Magee-Womens Research Institute

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity”.

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3659

N/A

1.7DataRank · unranked

34 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676

N/A

0DataRank · unranked

0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676.v1

N/A

0DataRank · unranked

0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more